Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure.

Close to 74,000 cases of renal cell carcinoma (RCC) are diagnosed each year in the United States. The past 2 decades have shown great developments in surgical techniques, targeted therapy and immunotherapy agents, and longer complete response rates. However, without a global cure, there is still room for further advancement in improving patient care in this space. To address some of the gaps restricting this progress, the Kidney Cancer Association brought together a group of 27 specialists across the areas of clinical care, research, industry, and advocacy at the inaugural "Think Tank: Coalition for a Cure" session. Topics addressed included screening, imaging, rarer RCC subtypes, combination drug therapy options, and patient response. This commentary summarizes the discussion of these topics and their respective clinical challenges, along with a proposal of projects for collaboration in overcoming those needs and making a greater impact on care for patients with RCC moving forward.

Clinical genitourinary cancer. 2020 Nov 14 [Epub ahead of print]

Brian Rini, E Jason Abel, Laurence Albiges, Axel Bex, James Brugarolas, Ronald M Bukowski, Jonathan A Coleman, Charles G Drake, Robert A Figlin, Andy Futreal, Hans Hammers, Thomas Powles, W Kimryn Rathmell, Christopher J Ricketts, Samra Turajlic, Christopher G Wood, Bradley C Leibovich

Medicine Department, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN. Electronic address: ., Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI., Department of Cancer Medicine, Genitourinary Group, Institut Gustave Roussy, Villejuif, France., Specialist Centre for Kidney Cancer, UCL Division of Surgery and Interventional Science, Royal Free London NHS Foundation Trust, London, England., Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX., Cleveland Clinic Foundation, Cleveland, OH., Weill-Cornell Medical Center, Department of Surgery, Urology, Memorial Sloan Kettering, New York, NY., Departments of Oncology & Urology, Columbia University Medical Center, New York, NY., Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA., Department of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX., Division of Hematology and Oncology, Kidney Cancer Program, St. Bartholomew's Hospital, London, England., Medicine Department, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN., Bart's Cancer Centre, National Cancer Institute, National Institutes of Health, Bethesda, MD., Medicine Department, Division of Hematology/Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, England., Urologic Oncology Branch, Center for Cancer Research, Mayo Clinic, Rochester, MN.